{"id":"W4390942391","doi":"10.1182/bloodadvances.2023012062","title":"Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Servier; Astellas Pharma; Chugai Pharmaceutical; Agios Pharmaceuticals; Astex Pharmaceuticals; Gilead Sciences; National Comprehensive Cancer Network; Eisai; Syndax Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Celgene; Universität Ulm; AstraZeneca; Pfizer; Amgen","keywords":"Refractory (planetary science); Chemotherapy; Medicine; Oncology; Internal medicine; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001093919,0.001114258,0.00199082,0.0002807418,0.0003079793,0.0008575746,0.00064564,0.00115939,0.005951407],"category_scores_gemma":[0.001194032,0.0003229179,0.001261791,0.0003663497,0.0007130352,0.0006535146,0.0003461836,0.002449317,0.0007213998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006639902,"about_ca_system_score_gemma":0.0007708439,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000742659,"about_ca_topic_score_gemma":0.001861424,"domain_scores_codex":[0.9995915,0.0002683313,0.0000167586,0.0000525794,0.00002106778,0.00004968347],"domain_scores_gemma":[0.9993912,0.0001807373,0.000140998,0.00005251605,0.00002724788,0.0002072924],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9801343,0.003141437,0.0005327088,0.000356877,0.0005843945,0.00003446272,0.00002863456,0.000298707,0.001308498,0.00009434797,0.0007811096,0.01270443],"study_design_scores_gemma":[0.9628311,0.03347982,0.001655072,0.00003254121,0.0004472588,0.00003826456,0.00002140276,0.000505904,0.0002875809,0.0001726166,0.0005178498,0.00001049471],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913899,0.00396662,0.0002298785,0.000751845,0.0002771344,0.001133665,0.0006111262,0.00007943918,0.001560392],"genre_scores_gemma":[0.9908099,0.001996547,0.0007052978,0.001180431,0.0002848237,0.00195401,0.000784789,0.00001941335,0.002264793],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005951407,"threshold_uncertainty_score":0.01990944,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01377240275022055,"score_gpt":0.3323051704801433,"score_spread":0.3185327677299227,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}